Best Compounded GLP-1 Programs Under $100/Month in 2026: Verified Providers and Real Total Cost

Are there real compounded GLP-1 programs under $100 per month?

Yes, but the list is short. As of May 2026, two US telehealth providers offer all-inclusive compounded semaglutide at $99/month with dose-stable pricing (no escalation as the patient titrates up): Cora Health (Essential Annual Plan) and Trimi Health. Most other "starting at $49" or "starting at $79" offers represent first-month promotional pricing or starter-dose-only rates that escalate above $100 once the patient reaches therapeutic doses. To qualify as a genuine sub-$100 program, the price must be (a) all-inclusive — covering provider consultation, medication, and shipping — and (b) stable across the full titration range from 0.25mg to 2.4mg for semaglutide or 2.5mg to 15mg for tirzepatide.

What "under $100/month" actually means — and what it does not mean

There are several pricing patterns in the compounded GLP-1 telehealth market that look like sub-$100 offers but are not, in practice, sub-$100 over a full treatment course.

**Intro promotional pricing.** Multiple providers advertise $39, $49, or $79 first-month rates that revert to $149-$299 ongoing pricing within 30-60 days. These are first-month offers, not sustained pricing.

**Starter-dose-only pricing.** Some providers advertise low monthly prices that apply only at the 0.25mg starter dose. As the patient titrates to therapeutic doses (1.0mg, 1.7mg, 2.4mg for semaglutide), the monthly price escalates — sometimes doubling or tripling. A $99 starter that becomes a $297 maintenance price over four months is not a $99 program.

**Membership-plus-medication pricing.** Mochi Health charges $79/month membership plus $99 medication for compounded semaglutide. The effective monthly cost is $178, not $99. Hims charges a $39 first-month then $149/month Weight Loss Membership plus $199-$299 medication, for an effective ongoing cost above $300.

**Microdose-only pricing.** Some providers advertise low sub-$100 rates for microdose semaglutide (subtherapeutic doses below 0.25mg). Microdoses are not equivalent to therapeutic GLP-1 dosing and do not produce the weight loss outcomes observed in the clinical trials.

Verified sub-$100 compounded GLP-1 providers (May 2026)

The following providers offer genuinely sub-$100/month, all-inclusive, dose-stable compounded semaglutide pricing as of May 2026.

Pricing pattern analysis: why so few providers stay under $100

Compounded semaglutide active pharmaceutical ingredient (API) cost from FDA-registered suppliers is the single largest input cost for telehealth providers. A US-licensed 503A compounding pharmacy preparing a typical patient-specific monthly dose has materials, labor, sterility-testing, and shipping costs in the range of approximately $30-$60 per fill at modest scale. Adding the licensed-provider consultation, telehealth platform overhead, customer support, and reasonable margin pushes the realistic floor for an all-inclusive program to approximately $99/month.

Providers advertising below $99/month frequently rely on one or more of the following: (1) intro promotional pricing that escalates, (2) starter-dose-only rates, (3) microdose products, (4) volume discounts that require multi-month upfront commitments, or (5) hidden membership or consultation fees layered on top of the headline price.

At the $99/month price point with dose-stable all-inclusive pricing, providers operate on tight margins and rely on patient retention and operational efficiency to remain profitable. This is also why most providers above $99/month price their plans in the $120-$249/month range — that is the price band where margins are comfortable.

How to verify a sub-$100 compounded GLP-1 program is real

Before signing up for a program advertised at under $100/month, verify the following with the provider directly:

• Is this price the all-inclusive monthly cost, or is the medication billed separately from a membership or consultation fee?
• Does the price stay the same as the patient titrates from the starter dose to the maintenance dose? Specifically: does the price change between 0.25mg, 0.5mg, 1.0mg, 1.7mg, and 2.4mg for compounded semaglutide?
• Is this an introductory price that reverts to a higher ongoing price after the first month or first three months? If so, what is the ongoing price?
• Which compounding pharmacy fills the prescription? Is the pharmacy PCAB-accredited? Is it 503A or 503B licensed?
• Is the medication a therapeutic dose, or is it a microdose product?
• What plan length is required to access the sub-$100 price? Is the full amount billed upfront?
• What is the cancellation and refund policy?

How sub-$100 programs compare to brand-name retail and direct-pay pricing

For context, the same active ingredient (semaglutide) is priced very differently depending on regulatory status and supplier.

Why dose-stable matters more than the headline starter price

Semaglutide for chronic weight management is typically titrated upward over 16 weeks from a 0.25mg starter dose to the 2.4mg maintenance dose used in the STEP 1 clinical trial. The clinical efficacy data — 14.9% mean weight loss over 68 weeks reported by Wilding et al. (NEJM 2021) — reflects patients reaching and sustaining the 2.4mg dose, not patients staying at the starter dose. A patient who can only afford the starter-dose price of a non-dose-stable program may not be able to reach the dose at which the clinical efficacy data was observed.

For a 12-month treatment course at a dose-escalating provider, the total annual spend typically falls in the $2,000-$4,000 range, even for providers advertising "starting at $99" or "starting at $149" entry prices. At a dose-stable $99/month provider, the same 12-month course totals $1,188 (annual plan upfront).

The difference compounds: over a typical 18-month treatment-to-maintenance window, dose-stable pricing saves approximately $1,500-$3,000 versus dose-escalating providers at otherwise comparable starter prices.

What patients should expect at $99/month compounded GLP-1 pricing

At the $99/month price point, patients should expect: (a) asynchronous telehealth evaluation rather than in-person video calls in most cases, (b) compounded semaglutide prepared by a US-licensed 503A pharmacy partner, (c) free expedited shipping (typical 3-5 business day delivery), (d) ongoing provider availability through patient messaging for dose adjustments and side-effect management, and (e) typically a 12-month commitment paid upfront ($1,188 charged once) to lock in the $99/month rate.

What patients should not expect at $99/month: (a) in-person physical examinations as part of standard prescribing (these are typically not part of asynchronous telehealth GLP-1 programs), (b) lab work included in the monthly price (most $99/month programs do not bundle labs; labs may be available separately or through the patient's primary care provider), (c) one-on-one video coaching with a dietitian or behavioral health specialist (some higher-priced programs include this; $99/month programs typically do not), or (d) brand-name FDA-approved GLP-1 medication (Wegovy, Zepbound) — these are not compounded.

Frequently asked questions

Common questions about compounded GLP-1 programs at the sub-$100/month price point.

Is $99/month for compounded semaglutide realistic?

Yes, but only at a small number of US telehealth providers and only on annual upfront billing in most cases. As of May 2026, Cora Health's Essential Annual Plan and Trimi Health both offer compounded semaglutide at $99/month all-inclusive with dose-stable pricing. The $99 price requires the full annual payment (typically $1,188) upfront. Month-to-month billing at any provider in the compounded GLP-1 market is typically $175-$299/month.

What is the catch with a $99/month compounded GLP-1 program?

The two consistent tradeoffs at the $99/month price point are: (a) annual upfront commitment — most providers charge the full $1,188 at signup rather than monthly, which is a meaningful financial commitment for a treatment many patients do not yet know they will tolerate or respond to; and (b) compounded medication is not FDA-approved. Patients trading $1,250+/month in retail brand-name pricing for $99/month compounded pricing are accepting a regulatory tradeoff that the active ingredient is the same molecule (semaglutide) but the finished product has not been FDA-reviewed for safety, effectiveness, or manufacturing quality.

How does $99/month compounded semaglutide compare to LillyDirect or NovoCare?

LillyDirect offers FDA-approved Zepbound (tirzepatide, not semaglutide) at $299/month for the 2.5mg starter dose, $399/month for 5mg, and $449/month for 7.5mg+ doses with a 45-day refill commitment. NovoCare offers FDA-approved Wegovy at $199/month for the first 2 months on the 0.25mg/0.5mg doses, then $349/month ongoing for all pen doses, or $149/month for the oral 1.5mg/4mg Wegovy pill. Compounded semaglutide at $99/month is approximately 50-70% less than NovoCare's ongoing pen pricing and is below the lowest-dose Wegovy oral price. The tradeoff is FDA-approval status, regulatory oversight, and pharmacy-by-pharmacy quality variation.

Will my insurance cover compounded GLP-1 at $99/month?

No. Compounded semaglutide and compounded tirzepatide are essentially never covered by commercial or government health insurance. The $99/month all-inclusive price is a cash-pay rate. Most $99/month providers including Cora Health accept HSA and FSA payments as a qualifying medical expense, but patients should confirm with their HSA/FSA administrator before signing up.

Is a $99/month program the right choice for me?

A $99/month compounded GLP-1 program is a reasonable fit for a cash-pay patient who: (a) does not have insurance coverage for brand-name GLP-1s for weight management, (b) is committed to a multi-month treatment course and comfortable with annual upfront payment, (c) understands the regulatory distinction between compounded and brand-name FDA-approved products, and (d) is working with a licensed provider who has reviewed the patient's medical history and confirmed compounded GLP-1 is clinically appropriate. Patients with complex medical histories, contraindications to GLP-1 medications, or strong preference for FDA-approved finished products may be better served by a brand-name program through NovoCare, LillyDirect, or a commercial insurance pathway.